Clinical trials: Klebsiella Pneumonia
Anti-Biotic Resistance, Klebsiella Pneumoniae
Probiotics for Eradication of Carbapenem Resistant Klebsiella Pneumonia
Infection by Klebsiella pneumonia producing class A carbapenemases is a major clinical and public health problem in Israel and worldwide.
- Trial name
- NCT00722410
- Testing
- VSL#3, Polyethylene glycol
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Hadassah Medical Organization
Carbapenem, Klebsiella Pneumonia
Double Carbapenem as Rescue Strategy for the Treatment of Carbapenemase-Producing Klebsiella Pneumoniae Infections
An observational two-center case-control study exploring the clinical impact of double-carbapenem use in a population of critically il patients with severe carbapenem-resistant Klebsiella pneumoniae infection
- Trial name
- NCT03094494
- Testing
- none intervention
- Volunteers
- 144 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Carriers of Carbapenem-resistant Klebsiella Pneumonia
SDD for Eradicating CRKP Carriage
There is an urgent need to control the current national outbreak of Carbapenem-resistent Klebsiella pneumonia (CRKP). In Israel, the death rate among CRKP carriers is 3.5 times higher than in Carbapenem-sensitive Klebsiella…
- Trial name
- NCT01761487
- Testing
- Gentamicin and polymyxin E
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Soroka University Medical Center
End-stage Renal Disease
The Incidence of Extended-spectrum β-lactamase (ESBL) Klebsiella Pneumonia in Patient on Renal Replacement Therapy
The prevalence of ESBL Klebsiella pneumonia was higher in patient with renal replacement therapy.
- Trial name
- NCT01612182
- Testing
- renal replacement therapy
- Where
- South Korea
- Volunteers
- 1,289 people
- Sponsor
- Inje University
P. Aeruginosa, Baumannii
An Open Clinical Trial of the Safety and Efficacy of the Drug Fluorothiazinone, 300 Mg Tablets with the Participation of Adult Patients with Chronic Bacterial Cystitis"
This study is designed to evaluate the safety, clinical efficacy and antibacterial activity of the drug Fluorothiazinone, 300 mg tablets, (Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the…
- Conditions
- P. Aeruginosa, Baumannii, Klebsiella Pneumonia, E.coli Infections
- Trial name
- NCT06815549
- Testing
- Fluorothiazinone, tablets 300 mg, Nitrofurantoin 100 MG
- Volunteers
- 280 people
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Ventilator Associated Pneumonia ( VAP), Mechanical Ventilation
Evaluation of the Role of Acetyl Cysteine in Ventilator Associated Pneumonia by Carbapenem Resistance Klebsiella
The aim of the study is to evaluate the role of addition of Acetyl cysteine in the management of VAP induced by carbapenem resistant klebsiella.
- Trial name
- NCT07097727
- Testing
- acetyl cysteine 600 mg, antibiotics and saline.
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Tanta University
Antimicrobial Resistance (AMR)
NCCR AntiResist:: New Approaches to Combat Antibiotic-resistant Bacteria
This is an explorative, mono-center study including prospectively collected patient samples from the University Hospital of Basel.
- Trial name
- AntiResist (NCT05017766)
- Testing
- analysis of antimicrobial resistance
- Where
- Switzerland
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Klebsiella Pneumoniae Carbapenemase Resistant Associated Bacteremia or Pneumonia
A Study Evaluating the Role of Oral Antibiotics in an Aim to Eradicate Carrier State of Carbapenem- Resistant Klebsiella Pneumonia (KPC).
Klebsiella pneumonia, inhabitant of the digestive tract, is a frequent nosocomial pathogen. It is currently the fourth most common cause of pneumonia and fifth most common cause of bacteremia in intensive care patients (1-3).
- Trial name
- NCT01266499
- Testing
- Colistin (Polymyxin E) 100mg x 4/d, both medications, will not receive PO treatment
- Where
- Israel
- Volunteers
- 200 people
- Sponsor
- Rambam Health Care Campus
Klebsiella Pneumonia, Bacteremia
Turkish Prospective Cohort Study on Carbapenem Resistant Klebsiella Pneumonia Bacteremia
Carbapenem-resistant Klebsiella pneumonia (CRKp) blood stream infections (BSI) cause substantial mortality among hospitalized patients.
- Trial name
- THREAT (NCT03597841)
- Testing
- Combination therapy
- Where
- 15 sites in Turkey (Türkiye)
- Volunteers
- 278 people
- Sponsor
- Koç University
Antibiotic Reaction
Antimicrobial Resistance Rate In Escherichia Coli And Klebsiella Pneumonia : A Retrospective Study
Antibiotics are medicines used to avoid and treat bacterial infections. Antibiotic resistance is increasing to dangerous level globally.
- Trial name
- NCT04196387
- Testing
- urine culture
- Volunteers
- 1,000 people
- Sponsor
- Batool Mutar
Escherichia Coli Infections, Klebsiella Pneumonia
Colonization With Extended-Spectrum Beta-Lactamase (ESBL)-Producing Organisms
There has been a great increase in the incidence of infections caused by bacteria that are resistant to antibiotic agents. Many of these infections result in worse outcomes of patients and increased costs to the healthcare…
- Trial name
- NCT01324726
- Where
- Lebanon
- Volunteers
- 100 people
- Sponsor
- American University of Beirut Medical Center
Klebsiella Pneumoniae Pneumonia
Fecal Microbiota Transplantation in Patients With Multiple Drug Resistant Klebsiella Pneumoniae Pneumonia
Multidrug-resistant Klebsiella pneumoniae (MDR-KP) infections account for 10% of all nosocomial infections, and even with effective antibiotics, the mortality rate is as high as 50%.
- Trial name
- NCT06641778
- Testing
- Fecal Microbiota Transplantation
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- luxia Kong
Ventilator-associated Pneumonia
Prognosis and Virulence Determination of Capsule and Endotoxin During Klebsiella Spp. Ventilator-associated Pneumonias
Ventilator-associated pneumonia is the leading cause of nosocomial infection in the ICU. The pathogens responsible are multiple, but enterobacteria constitute a major source of pathogens involved.
- Trial name
- PROVIDENCE (NCT05450796)
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Pneumonia, Bloodstream Infection
Clinical Outcomes in Patients With Infection by Resistant Microorganism
The goal of this individual patient data meta-analysis is to estimate the attributed and the associated health burden related to bloodstream infections, pneumonia, skin and soft tissue infections, surgical site infections and…
- Conditions
- Pneumonia, Bloodstream Infection, Urinary Tract Infections, Skin Infection
- Trial name
- NCT05880069
- Testing
- Pathogen resistant phenotype
- Where
- Spain
- Volunteers
- 5,000 people
- Sponsor
- Hospital Universitario Virgen Macarena
Bloodstream Infection, Pneumonia, Bacterial
Development of Risk Score Model and Decision Tree Algorithm for Predicting Infections With CRKp in Colonized Patients
DETERMINE trial is a prospective multicenter multinational cohort study. This study will be carried out to predict the risk of bloodstream infections (BSIs) or other types of invasive infection with carbapenem resistant…
- Conditions
- Bloodstream Infection, Pneumonia, Bacterial, Intra-abdominal Infection, Urinary Tract Infections
- Trial name
- DETERMINE (NCT04229511)
- Testing
- Detection of CRKp colonization
- Where
- Turkey (Türkiye)
- Volunteers
- 520 people
- Sponsor
- SCARE (Study group for carbapenem resistance)
Bacteremia
Detecting Infections Rapidly and Easily for Bacteremia Trial (DIREBT)
To assure the uniform collection, handling, storage and transport of patient whole blood specimens and associated information to support validation of the T2 Bacteremia Assay.
- Trial name
- DIREBT (NCT01919762)
- Where
- United States
- Volunteers
- 156 people
- Sponsor
- T2 Biosystems